

## EAP

[View the current EAP Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/3648-EAP.html) (<http://www.bioportfolio.com/biocorporate/3648-EAP.html>)

### Contact Details:

71 St. Mary's Road  
Oxford  
Oxfordshire  
OX4 1QB  
United Kingdom

Tel: 07947788536

Fax:

Email:

### Recent Publications by EAP:



- [Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.](#)  
*Resistance to CCR5 antagonists can be driven by mutations in gp120...*4th October, 2008  
aUMPC Universite Paris 06, France bAP-HP, Laboratoire de Virologie,- AIDS. 2008 Oct 18;22(16):2212-2214. ([DOI Direct Link](#))
- [\[Abdominal obesity and cardiometabolic risk\]](#)  
*OBJECTIVE: The effects on periodontal tissues of adjacent second molars...*17th September, 2008  
EAP Raval Sud, Institut Catala de la Salut,Avda, Drassanes 17-21, 08001- Aten Primaria. 2008 Apr;40(4):199-204.
- [\[Efficacy of an intensive prevention programme of coronary heart disease: 5 year follow-up outcomes\]](#)  
*BACKGROUND AND OBJECTIVE: Most evidence on the efficacy of intensive...*5th September, 2008  
EAP Montornes-Montmelo, Institut Catala de la Salut, Montmelo, Barcelona,- Med Clin (Barc). 2008 Apr 19;130(14):521-5.
- [Development of autoimmune diseases after vaccination.](#)  
*Resistance to CCR5 antagonists can be driven by mutations in gp120...*4th September, 2008  
EAP Encants, ICS, Servei de Medicina Interna, Hospital de la Santa Creu i- J Clin Rheumatol. 2008 Aug;14(4):243-4. ([DOI Direct Link](#))
- [\[Controversies on the diagnosis and treatment of attention-deficit hyperactivity disorder.\]](#)  
*Resistance to CCR5 antagonists can be driven by mutations in gp120...*30th August, 2008  
EAP La Gavarra. Institut Catala de la Salut. SAP Baix Llobregat Centre.- Aten Primaria. 2008 Aug;40(8):426-7.
- [How are we using SMBG in our Type 2 diabetic patients?](#)

- Resistance to CCR5 antagonists can be driven by mutations in gp120....*18th July, 2008  
EAP Sant Marti. Institut Catala de la Salut, C/ Beethoven 6-10, 3er 1a,- Prim Care Diabetes. 2007 Dec;1(4):226. ([DOI Direct Link](#))
- [\[Safety of iodine supplementation during pregnancy in mild-to-moderate iodine deficient areas\]](#)  
*Resistance to CCR5 antagonists can be driven by mutations in gp120....*28th June, 2008  
Medicina Familiar y Comunitaria, EAP Villarejo de Salvanes, Servicio- Med Clin (Barc). 2008 Jun 7;131(1):22-9.
  - [\[Quality of life in homebound elderly people in a district of Alicante \(Spain\)\]](#)  
*OBJECTIVE: To measure health-related quality of life (HRQoL) in homebound...*5th June, 2008  
EAP, Centro de Salud de San Blas, Departamento de Salud 19, Alicante,- Enferm Clin. 2007 Nov-Dec;17(6):287-92.
  - [\[Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multi-centre randomized controlled clinical trial.\]](#)  
*ABSTRACT: BACKGROUND: Influenza vaccines are recommended for...*30th May, 2008  
EAP Gotic, Institut Catala de la Salut, Passatge de la Pau 1, 08001- BMC Blood Disord. 2008 May 29;8:1. ([DOI Direct Link](#))
  - [\[Effects of surgical removal of mandibular third molar on the periodontium of the second molar.\]](#)  
*OBJECTIVE: The effects on periodontal tissues of adjacent second molars...*20th May, 2008  
Department of Maxillofacial Surgery, EAP, APCD, Piracicaba, SP, Brazil.- Int J Dent Hyg. 2008 May;6(2):123-8. ([DOI Direct Link](#))
  - [\[Forecast of effort\]](#)  
*OBJECTIVE: To determine the reasons for undergoing or rejecting influenza...*30th April, 2008  
Medicina de Familia, EAP Gavarra, ICS, Departamento de Ciencias Clinicas,- Aten Primaria. 2007 Oct;39(10):569-71.
  - [\[Undetectable serum anti-Mullerian hormone levels and occurrence of ongoing pregnancy.\]](#)  
*OBJECTIVE: To discuss, on the basis of the experience of two clinical...*28th March, 2008  
Unite d'Endocrinologie Gynecologique et Medecine de la Reproduction,- Fertil Steril. 2008 Mar;89(3):723.e9-11. Epub 2007 Jun 11. ([DOI Direct Link](#))
  - [\[Attitudes toward influenza vaccination in an urban population older than 60 years\]](#)  
*OBJECTIVE: To determine the reasons for undergoing or rejecting influenza...*4th March, 2008  
EAP Dreta de- Enferm Clin. 2007 Sep-Oct;17(5):239-45.
  - [\[Paget disease of the breast\]](#)  
*OBJECTIVE: To determine the reasons for undergoing or rejecting influenza...*25th January, 2008  
EAP Gotic. Hospital del Mar. Barcelona. Espana.- Med Clin (Barc). 2007 Sep 29;129(11):440.
  - [\[The effect of environmental factors on technical and scale efficiency of primary health care providers in Greece.\]](#)  
*ABSTRACT: BACKGROUND: The purpose of this study was to compare technical...*21st November, 2007  
Hellenic Open University, Faculty of Social Sciences, Riga Feraiou 169 &- Cost Eff Resour Alloc. 2007 Nov 17;5:14. ([DOI Direct Link](#))

## BioNews Results for EAP



- [\[Flu drug makers urge employers to stock up\]](#)  
*STLtoday.com: Sep 27 2008 8:17AM Matching: eap*
- [\[IDIS to Sponsor Inaugural Conference on Pre-Launch Access to Drugs\]](#)  
*Pharma Live: Sep 19 2008 3:58AM Matching: eap*

- [AssureRx Enters Into Strategic Relationship with Diamond Healthcare Corporation](#)  
*KSLA: Sep 18 2008 7:53PM Matching: eap*
- [AssureRx Enters Into Strategic Relationship with Diamond Healthcare Corporation](#)  
*KLFY: Sep 18 2008 7:17PM Matching: eap*
- [Gilead receives complete response letter from U.S. Food and Drug Administration for Aztreonam Lysine for inhal](#)  
*Checkbiotech: Sep 18 2008 4:46PM Matching: eap*
- [Gilead receives complete response letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhal](#)  
*Checkbiotech: Sep 18 2008 2:18PM Matching: eap*
- [Gilead Receives Complete Response Letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhal](#)  
*DiGiTAL50: Sep 17 2008 6:52AM Matching: eap*
- [Gilead Sciences Receives Complete Response Letter From FDA Disapproving New Drug Application For aztreonam lys](#)  
*RTTNews.com: Sep 17 2008 12:49AM Matching: eap*
- [Gilead Receives Complete Response Letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhal](#)  
*FinanzNachrichten.de: Sep 16 2008 11:22PM Matching: eap*
- [Gilead Receives Complete Response Letter from U.S. Food and Drug Administration for Aztreonam Lysine for Inhal](#)  
*Business Wire via Yahoo!: Sep 16 2008 11:09PM Matching: eap*
- [Gilead Receives Complete Response Letter from U.S. Food and Drug](#)  
*Business Wire via MSN Money: Sep 16 2008 11:06PM Matching: eap*
- [Effective Management of ADHD During Patient Transitions](#)  
*Abstracts in Hematology and Oncology: Sep 11 2008 7:11PM Matching: eap*
- [Port Huron Hospital Mental Health Services](#)  
*Port Huron Times-Herald: Sep 9 2008 2:21AM Matching: eap*
- [WellPoint Adjusts Health and Pharmacy Guidelines for Members Affected by Hurricane Ike](#)  
*Montana's News Station: Sep 8 2008 12:17AM Matching: eap*
- [WellPoint Adjusts Health and Pharmacy Guidelines for Members Affected by Hurricane Ike](#)  
*Pharma Live: Sep 8 2008 4:25PM Matching: eap*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

